Predictive Value of Blood and Bone Marrow Flow Cytometry in B-Cell Lymphoma Classification: Comparative Analysis of Flow Cytometry and Tissue Biopsy in 252 Patients

Morice, William G.; Kurtin, Paul J.; Hodnefield, Janice M.; Shanafelt, Tait D.; Hoyer, James D.; Remstein, Ellen D.; Hanson, Curtis A.
July 2008
Mayo Clinic Proceedings;Jul2008, Vol. 83 Issue 7, p776
Academic Journal
OBJECTIVE: To study the effectiveness of peripheral blood (PB) and bone marrow flow cytometric immunophenotyping (FCIP) in predicting the histologic B-cell lymphoma type. PATIENTS AND METHODS: We studied the FCIP results and tissue histopathology from 252 patients with B-cell lymphoma seen at Mayo Clinic's site in Rochester, MN, between January 1, 1997, and January 1, 2004, who had positive results on PB, bone marrow, or body fluid FCIP and a corresponding diagnostic tissue biopsy specimen. RESULTS: Most of the B-cell lymphomas studied were low grade, with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma being most common. Row cytometric immunophenotyping histogram analysis was more informative than tabulated percentage antigen positivity; surface immunoglobulin and CD20 staining intensity, CD5 and CD23 positivity, CD10 positivity, and the coexpression of CD11c/CD22 and CD103 were the most pertinent markers. Using these FCIP parameters and strict immunophenotypic definitions for CLL, mantle cell lymphoma (MCL), and hairy cell leukemia, we obtained greater than 95% specificity for each diagnosis. However, we encountered the following exceptions to standard paradigms of B-cell lymphoma-associated FCIP: (1) CD5 expression by disorders distinct from CLL and MCL, (2) lack of uniform CD5 positivity in some CLL and MCL cases, (3) absence of CD10 in approximately 50% of follicular lymphomas, and (4) expression of CD103 by occasional marginal zone lymphomas. CONCLUSION: Stringent interpretation of PB and bone marrow FCIP results enables identification of certain B-cell lymphoma types. However, the observed exceptions to accepted immunophenotypic paradigms highlight the occasional phenotypic overlap among diseases and emphasize that a systematic approach to FCIP interpretations is key to providing clinically useful diagnostic information.


Related Articles

  • Spotlight on Rituximab in Chronic Lymphocytic Leukemia, Low-Grade or Follicular Lymphoma, and Diffuse Large B-Cell Lymphoma.  // BioDrugs;2011, Vol. 25 Issue 1, p55 

    No abstract available.

  • Expression of heat-shock protein-90 in non-Hodgkin's lymphomas. Valbuena, Jose R.; Rassidakis, George Z.; Lin, Pei; Atwell, Coralyn; Georgakis, Georgios V.; Younes, Anas; Jones, Dan; Medeiros, L. Jeffrey // Modern Pathology;Oct2005, Vol. 18 Issue 10, p1343 

    Heat-shock protein-90 (HSP90) inhibitors are currently being used in phase I clinical trials for treating patients with a variety of neoplasms including lymphomas. Using immunohistochemical methods, we assessed for HSP90 expression in 412 cases of non-Hodgkin's lymphoma. In B-cell lymphomas,...

  • Clinical Prognostic Biomarkers in Chronic Lymphocytic Leukemia and Diffuse Large B-Cell Lymphoma. Chastain, Elizabeth C.; Duncavage, Eric J. // Archives of Pathology & Laboratory Medicine;May2015, Vol. 139 Issue 5, p602 

    Context.—Diffuse large B-cell lymphoma and chronic lymphocytic leukemia are 2 of the most common B-cell lymphomas in adults. Both diffuse large B-cell lymphoma and chronic lymphocytic leukemia share heterogeneous outcomes, and the use of prognostic biomarkers to better stratify risk in...

  • Diagnostic Usefulness and Prognostic Impact of CD200 Expression in Lymphoid Malignancies and Plasma Cell Myeloma. Alapat, Daisy; Coviello-Malle, Jean; Owens, Rebecca; Qu, Pingping; Barlogie, Bart; Shaughnessy, John D.; Lorsbach, Robert B. // American Journal of Clinical Pathology;Jan2012, Vol. 137 Issue 1, p93 

    The membrane glycoprotein MRC OX-2 (CD200) is expressed in several lymphoid malignancies. However, the diagnostic usefulness and potential prognostic importance of CD200 expression have not been rigorously examined. We show that CD200 is uniformly expressed in chronic lymphocytic leukemia (CLL)...

  • Leukemic Phase of B-Cell Lymphomas Mimicking Chronic Lymphocytic Leukemia and Variants at Presentation. Nelson, Beverly P.; Variakojis, Daina; Peterson, LoAnn C. // Modern Pathology;Nov2002, Vol. 15 Issue 11, p1111 

    Six cases of non-Hodgkin B-cell lymphoma that mimicked either chronic lymphocytic leukemia (CLL) or a CLL variant at presentation are reported. The patients ranged from 54 to 89 years and included three females and three males. All six patients had prominent peripheral blood lymphocytosis at...

  • Normal Syk protein level but abnormal tyrosine phosphorylation in B-CLL cells. Semichon, M; Merle-Béral, H; Lang, V; Bismuth, G // Leukemia (08876924);Nov97, Vol. 11 Issue 11, p1921 

    One characteristic of B cells that accumulate during chronic lymphocytic leukemia (CLL) is their highly heterogeneous functional responses to B cell receptor (BCR) stimulation. Leukemic B cells with very poor responses have defective rapid tyrosine phosphorylation of numerous substrates,...

  • Utility of the Bone-marrow Exam for Complete Remission in Myeloma. Artz, Andrew S. // Clinical Oncology Alert;Nov2009, Vol. 25 Issue 11, p82 

    The article discusses research on evaluating the response of a patient with multiple myeloma (MM) to treatment through bone-marrow (BM) examination. It references the study "The Importance of Bone Marrow Examination in Determining Complete Response to Therapy in Patient With Multiple Myeloma,"...

  • Obinutuzumab: First Global Approval. Cameron, Fiona; McCormack, Paul // Drugs;Jan2014, Vol. 74 Issue 1, p147 

    Obinutuzumab (Gazyvaâ„¢) is an intravenously administered, humanized and glycoengineered, type II anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. It is approved in the US for use in combination with chlorambucil for the first-line treatment of chronic lymphocytic...

  • Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells. Hahntow, I. N.; SchnelIer, F.; Oelsner, M.; Weick, K.; Ringshausen, I.; Fend, F.; Peschel, C.; Decker, T.; Schneller, F // Leukemia (08876924);Apr2004, Vol. 18 Issue 4, p747 

    A new class of cell cycle inhibitors is currently entering clinical trials. These drugs exert their activity by inhibition of cyclin-dependent kinases (cdk) and induce cell cycle arrest and apoptosis in cancer cells. Roscovitine, a cdk2-inhibitor that is in preclinical evaluation, induced...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics